Clinically superior scalp cooling
Hair loss is no longer inevitable
FDA cleared for men and women with solid tumor cancers
Clinically superior scalp cooling
Hair loss is no longer inevitable
FDA cleared for men and women with solid tumor cancers

Dignitana AB produces
The DigniCap Scalp Cooling System to minimize hair loss from chemotherapy.

Click HERE to learn more about DigniCap Delta.

The patented DigniCap system has shown excellent scientific results in clinical studies– 67% of patients had a successful outcome and retained their hair in the pivotal trial which led to FDA clearance in 2015.

For product information, visit dignicap.com

ABOUT DIGNITANA READ MORE

Company Profile

Dignitana is a Swedish medical technology company publicly traded on Nasdaq First North Growth Market. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy.

The company develops, produces and markets The DigniCap® Scalp Cooling System. It is a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. In 2017, Dignitana received an expanded clearance from the FDA, allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lungs and other tissues.

LATEST PRESS RELEASES

ANNOUNCEMENTS

NOTICE OF EXTRAORDINARY GENERAL MEETING

The shareholders of Dignitana AB (publ) reg. no. 556730-5346 (the “Company”) are hereby given notice to attend the Extraordinary General Meeting (the “EGM”) on 12 March 2024 at 15.00 CET at Turning Torso, Lilla Varvsgatan 14, 211 15 in Malmö. Registration starts at 14.30 CET.   

Visit the EGM page here

 

ANALYSIS

Dignitana: interview with CEO Catarina Löwenadler (video in Swedish)

15 February 2024

Dignitana CEO Catarina Löwenadler was interviewed by Redeye analyst Mats Hyttinge regarding the company’s latest activities and the Q4 Interim Report titled “Positive EBITDA, continued growth and high margin.” Watch the video interview in Swedish here:

VIDEOS

Saving Identity
1 September 2019
In the film “Saving Identity” Dr. Hope Rugo of UCSF explains how scalp cooling reduces hair loss from chemo and the process from gaining approval for the first FDA cleared scalp cooling system in the US in 2015 to the launch of the new DigniCap Delta device in 2019.

Please note that the content of this website is not intended as professional medical or healthcare advice and should not be construed as a substitute for professional healthcare advice, or services from a qualified professional healthcare provider familiar with your unique situation. This content is intended solely as a general product and corporate information.

OPERATIONS
Dignitana
10925 Estate Lane, Suite 185
Dallas, TX 75238
+1 469-917-5555

HEADQUARTERS
Dignitana AB
Traktorgränden 3
226 60 Lund, Sweden
+46 46 16 30 90

HEADQUARTERS
Dignitana S.r.l.
Corso di Porta Nuova, 46
20121 Milan, Italy